Lenghe Zhang
YOU?
Author Swipe
View article: Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies
Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies Open
Molecular targeted drugs and chimeric antigen receptor (CAR) T cell therapy represent specific biological treatments that have significantly improved the efficacy of treating hematologic malignancies. However, they face challenges such as …
View article: Deep learning-based transcriptome model predicts survival of T-cell acute lymphoblastic leukemia
Deep learning-based transcriptome model predicts survival of T-cell acute lymphoblastic leukemia Open
Identifying subgroups of T-cell acute lymphoblastic leukemia (T-ALL) with poor survival will significantly influence patient treatment options and improve patient survival expectations. Current efforts to predict T-ALL survival expectation…
View article: Dual targeting of NUAK1 and ULK1 using the multitargeted inhibitor MRT68921 exerts potent antitumor activities
Dual targeting of NUAK1 and ULK1 using the multitargeted inhibitor MRT68921 exerts potent antitumor activities Open
Utilizing oxidative stress has recently been regarded as a potential strategy for tumor therapy. The NUAK family SNF1-like kinase 1 (NUAK1) is a critical component of the antioxidant defense system and is necessary for the survival of tumo…
View article: GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo
GZD824 as a FLT3, FGFR1 and PDGFRα Inhibitor Against Leukemia In Vitro and In Vivo Open
GZD824 is a novel third-generation BCR-ABL inhibitor. It entered Phase II clinical trials in China and Phase Ib clinical trials in USA in 2019 for treatment of patients with resistant chronic myeloid leukemia (CML). We found that at concen…
View article: Shortening the ex vivo culture of CD19‐specific CAR T‐cells retains potent efficacy against acute lymphoblastic leukemia without CAR T‐cell‐related encephalopathy syndrome or severe cytokine release syndrome
Shortening the ex vivo culture of CD19‐specific CAR T‐cells retains potent efficacy against acute lymphoblastic leukemia without CAR T‐cell‐related encephalopathy syndrome or severe cytokine release syndrome Open
Genetically transduced chimeric antigen receptor (CAR) T-cells targeting CD19 represent a revolutionary immunotherapy in the field of B-lineage malignancies. They have been reported to induce an 83-93% response rate in patients with refrac…
View article: A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation
A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation Open
View article: Dual Targeting of NUAK1 and ULK1 Using the Multitargeted Inhibitor MRT68921 Exerts Potent Antitumor Activities
Dual Targeting of NUAK1 and ULK1 Using the Multitargeted Inhibitor MRT68921 Exerts Potent Antitumor Activities Open